Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer

Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer

There is an unmet need to improve the response to immune checkpoint blockade in patients with head and neck squamous cell carcinoma (HNSCC). Here the authors show that aberrant HER3 activation sustains the proliferation of PIK3CA wild type HNSCC cells and that HER3 inhibition increases response to P...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Zhiyong Wang, Yusuke Goto, Michael M. Allevato, Victoria H. Wu, Robert Saddawi-Konefka, Mara Gilardi, Diego Alvarado, Bryan S. Yung, Aoife O’Farrell, Alfredo A. Molinolo, Umamaheswar Duvvuri, Jennifer R. Grandis, Joseph A. Califano, Ezra E. W. Cohen, J. Silvio Gutkind
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/5c6d1bf166824a7299c38c08b6124d71
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:There is an unmet need to improve the response to immune checkpoint blockade in patients with head and neck squamous cell carcinoma (HNSCC). Here the authors show that aberrant HER3 activation sustains the proliferation of PIK3CA wild type HNSCC cells and that HER3 inhibition increases response to PD-1 blockade in HNSCC preclinical models.

Ejemplares similares